Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Aug 27, 2024
- Accession no.
- 0001447362-24-000137
- Filed
- Aug 27, 2024
- Trade date
- Aug 23-26, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $89.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2024 | Common Stock | SSaleDisposed | −1,037 | $30.09F2 | −$31,203.33 | 102,019 | Direct | |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −534 | $30.09F2 | −$16,068.06 | 81,948 | Indirect | |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −534 | $30.09F2 | −$16,068.06 | 70,845 | Indirect | |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −171 | $30.09F2 | −$5,145.39 | 8,356 | Indirect | |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −169 | $30.09F2 | −$5,085.21 | 8,356 | Indirect | |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −169 | $30.09F2 | −$5,085.21 | 8,356 | Indirect | |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −169 | $30.09F2 | −$5,085.21 | 8,356 | Indirect | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −76 | $30.05F9 | −$2,283.8 | 101,943 | Direct | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −39 | $30.05F9 | −$1,171.95 | 81,909 | Indirect | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −39 | $30.05F9 | −$1,171.95 | 70,806 | Indirect | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −14 | $30.05F9 | −$420.7 | 8,342 | Indirect | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −12 | $30.05F9 | −$360.6 | 8,344 | Indirect | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −12 | $30.05F9 | −$360.6 | 8,344 | Indirect | |
| Aug 26, 2024 | Common Stock | SSaleDisposed | −12 | $30.05F9 | −$360.6 | 8,344 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $30.00 to $30.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $30.020 to $30.075, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.